natgillin/translations-raw huggingface dataset:
The approval periods of the active substances 2,4-DB, beta-cyfluthrin, Coniothyrium minitans Strain CON/M/91-08 (DSM 9660), deltamethrin, dimethenamid-P, flufenacet, flurtamone, fosthiazate, iodosulfuron, iprodione, maleic hydrazide, picoxystrobin and silthiofam were derogated from by Regulation (EU) No 823/2012.
Uredbom (EU) br. 823/2012 predviđeno je odstupanje za rokove valjanosti odobrenja aktivnih tvari 2,4-DB, beta-ciflutrin, Coniothyrium minitans soja CON/M/91-08 (DSM 9660), deltametrin, dimetenamid-P, flufenacet, flurtamon, fostiazat, jodosulfuron, iprodion, malein hidrazid, pikoksistrobin i siltiofam.
The approval of these substances will expire on 31 October 2016.
Odobrenje tih tvari prestaje važiti 31. listopada 2016.
Applications for the renewal of the approval of those substances were submitted in accordance with Commission Implementing Regulation (EU) No 844/2012 [4].
Zahtjevi za obnavljanje odobrenja tih tvari podneseni su u skladu s Provedbenom uredbom Komisije (EU) br. 844/2012 [4].
It is therefore necessary to extend their approval periods.
Stoga je potrebno produljiti rokove valjanosti tih odobrenja.
In view of the aim of the first paragraph of Article 17 of Regulation (EC) No 1107/2009, as regards cases where the Commission will adopt a Regulation providing that the approval of an active substance referred to in the Annex to this Regulation is not renewed because the approval criteria are not satisfied, the Commission will set the expiry date at the same date as before this Regulation or at the date of the entry into force of the Regulation providing that the approval of the active substance is not renewed, whichever date is later.
S obzirom na cilj članka 17. stavka 1. Uredbe (EZ) br. 1107/2009 u slučajevima u kojima će Komisija donijeti uredbu kojom se predviđa da se odobrenje aktivne tvari iz Priloga ovoj Uredbi ne obnavlja jer nisu ispunjena mjerila za odobrenje, Komisija će kao datum prestanka valjanosti odrediti isti datum koji je vrijedio prije donošenja ove Uredbe ili datum stupanja na snagu uredbe kojom se predviđa da se odobrenje aktivne tvari ne obnavlja, ovisno o tome koji je datum kasniji.
As regards cases where the Commission will adopt a Regulation providing for the renewal of an active substance referred to in the Annex to this Regulation, the Commission will endeavour to set, as appropriate under the circumstances, the earliest possible application date.
U slučajevima u kojima Komisija donese uredbu o obnavljanju aktivne tvari iz Priloga ovoj Uredbi, Komisija će nastojati, u skladu s okolnostima, odrediti najraniji mogući datum primjene.
Done at Brussels, 15 June 2016.
Sastavljeno u Bruxellesu 15. lipnja 2016.
in the sixth column, expiration of approval, of row 29, Ethofumesate, the date is replaced by ‘31 July 2017’;
U šestom stupcu, prestanak odobrenja, u retku 29., etofumesat, datum se zamjenjuje datumom „31. srpnja 2017.”
in the sixth column, expiration of approval, of row 40, Deltamethrin, the date is replaced by ‘31 October 2017’;
U šestom stupcu, prestanak odobrenja, u retku 40., deltametrin, datum se zamjenjuje datumom „31. listopada 2017.”
in the sixth column, expiration of approval, of row 41, Imazamox, the date is replaced by ‘31 July 2017’;
U šestom stupcu, prestanak odobrenja, u retku 41., imazamoks, datum se zamjenjuje datumom „31. srpnja 2017.”
in the sixth column, expiration of approval, of row 42, Oxasulfuron, the date is replaced by ‘31 July 2017’;
U šestom stupcu, prestanak odobrenja, u retku 42., oksasulfuron, datum se zamjenjuje datumom „31. srpnja 2017.”
in the sixth column, expiration of approval, of row 44, Foramsulfuron, the date is replaced by ‘31 July 2017’;
U šestom stupcu, prestanak odobrenja, u retku 44., foramsulfuron, datum se zamjenjuje datumom „31. srpnja 2017.”
in the sixth column, expiration of approval, of row 46, Cyazofamid, the date is replaced by ‘31 July 2017’;
U šestom stupcu, prestanak odobrenja, u retku 46., ciazofamid, datum se zamjenjuje datumom „31. srpnja 2017.”
in the sixth column, expiration of approval, of row 47, 2,4-DB, the date is replaced by ‘31 October 2017’;
U šestom stupcu, prestanak odobrenja, u retku 47., 2,4-DB, datum se zamjenjuje datumom „31. listopada 2017.”
in the sixth column, expiration of approval, of row 48, Beta-cyfluthrin, the date is replaced by ‘31 October 2017’;
U šestom stupcu, prestanak odobrenja, u retku 48., beta-ciflutrin, datum se zamjenjuje datumom „31. listopada 2017.”
in the sixth column, expiration of approval, of row 50, Iprodione, the date is replaced by ‘31 October 2017’;
U šestom stupcu, prestanak odobrenja, u retku 50., iprodion, datum se zamjenjuje datumom „31. listopada 2017.”
in the sixth column, expiration of approval, of row 51, Linuron, the date is replaced by ‘31 July 2017’;
U šestom stupcu, prestanak odobrenja, u retku 51., linuron, datum se zamjenjuje datumom „31. srpnja 2017.”
in the sixth column, expiration of approval, of row 52, Maleic hydrazide, the date is replaced by ‘31 October 2017’;
U šestom stupcu, prestanak odobrenja, u retku 52., malein hidrazid, datum se zamjenjuje datumom „31. listopada 2017.”
in the sixth column, expiration of approval, of row 53, Pendimethalin, the date is replaced by ‘31 July 2017’;
U šestom stupcu, prestanak odobrenja, u retku 53., pendimetalin, datum se zamjenjuje datumom „31. srpnja 2017.”
in the sixth column, expiration of approval, of row 59, Trifloxystrobin, the date is replaced by ‘31 July 2017’;
U šestom stupcu, prestanak odobrenja, u retku 59., trifloksistrobin, datum se zamjenjuje datumom „31. srpnja 2017.”
in the sixth column, expiration of approval, of row 60, Carfentrazone ethyl, the date is replaced by ‘31 July 2017’;
U šestom stupcu, prestanak odobrenja, u retku 60., karfentrazon etil, datum se zamjenjuje datumom „31. srpnja 2017.”
in the sixth column, expiration of approval, of row 61, Mesotrione, the date is replaced by ‘31 July 2017’;
U šestom stupcu, prestanak odobrenja, u retku 61., mezotrion, datum se zamjenjuje datumom „31. srpnja 2017.”
in the sixth column, expiration of approval, of row 62, Fenamidone, the date is replaced by ‘31 July 2017’;
U šestom stupcu, prestanak odobrenja, u retku 62., fenamidon, datum se zamjenjuje datumom „31. srpnja 2017.”
in the sixth column, expiration of approval, of row 63, Isoxaflutole, the date is replaced by ‘31 July 2017’;
U šestom stupcu, prestanak odobrenja, u retku 63., izoksaflutol, datum se zamjenjuje datumom „31. srpnja 2017.”
in the sixth column, expiration of approval, of row 64, Flurtamone, the date is replaced by ‘31 October 2017’;
U šestom stupcu, prestanak odobrenja, u retku 64., flurtamon, datum se zamjenjuje datumom „31. listopada 2017.”
in the sixth column, expiration of approval, of row 65, Flufenacet, the date is replaced by ‘31 October 2017’;
U šestom stupcu, prestanak odobrenja, u retku 65., flufenacet, datum se zamjenjuje datumom „31. listopada 2017.”
in the sixth column, expiration of approval, of row 66, Iodosulfuron, the date is replaced by ‘31 October 2017’;
U šestom stupcu, prestanak odobrenja, u retku 66., jodosulfuron, datum se zamjenjuje datumom „31. listopada 2017.”
in the sixth column, expiration of approval, of row 67, Dimethenamid-P, the date is replaced by ‘31 October 2017’;
U šestom stupcu, prestanak odobrenja, u retku 67., dimetenamid-P, datum se zamjenjuje datumom „31. listopada 2017.”
in the sixth column, expiration of approval, of row 68, Picoxystrobin, the date is replaced by ‘31 October 2017’;
U šestom stupcu, prestanak odobrenja, u retku 68., pikoksistrobin, datum se zamjenjuje datumom „31. listopada 2017.”
in the sixth column, expiration of approval, of row 69, Fosthiazate, the date is replaced by ‘31 October 2017’;
U šestom stupcu, prestanak odobrenja, u retku 69., fostiazat, datum se zamjenjuje datumom „31. listopada 2017.”
in the sixth column, expiration of approval, of row 70, Silthiofam, the date is replaced by ‘31 October 2017’;
U šestom stupcu, prestanak odobrenja, u retku 70., siltiofam, datum se zamjenjuje datumom „31. listopada 2017.”
in the sixth column, expiration of approval, of row 71, Coniothyrium minitans Strain CON/M/91-08 (DSM 9660), the date is replaced by ‘31 October 2017’.
U šestom stupcu, prestanak odobrenja, u retku 71., Coniothyrium minitans soj CON/M/91-08 (DSM 9660), datum se zamjenjuje datumom „31. listopada 2017.”
Commission Implementing Regulation (EU) 2016/951
Provedbena uredba Komisije (EU) 2016/951
approving the low-risk active substance Trichoderma atroviride strain SC1, in accordance with Regulation (EC) No 1107/2009 of the European Parliament and of the Council concerning the placing of plant protection products on the market, and amending the Annex to Commission Implementing Regulation (EU) No 540/2011
o odobravanju aktivne tvari niskog rizika Trichoderma atroviride soj SC1 u skladu s Uredbom (EZ) br. 1107/2009 Europskog parlamenta i Vijeća o stavljanju na tržište sredstava za zaštitu bilja i o izmjeni priloga Provedbenoj uredbi Komisije (EU) br. 540/2011
In accordance with Article 7(1) of Regulation (EC) No 1107/2009, France received on 6 November 2012 an application from BI-PA NV for the approval of the active substance Trichoderma atroviride strain SC1.
U skladu s člankom 7. stavkom 1. Uredbe (EZ) br. 1107/2009 Francuska je 6. studenoga 2012. primila zahtjev od subjekta BI-PA NV za odobrenje aktivne tvari Trichoderma atroviride soj SC1.
In accordance with Article 9(3) of that Regulation, France, as rapporteur Member State, notified the Commission on 5 February 2013 of the admissibility of the application.
U skladu s člankom 9. stavkom 3. te Uredbe Francuska je, kao država članica izvjestiteljica, 5. veljače 2013. Komisiju obavijestila o prihvatljivosti zahtjeva.
On 27 May 2014, the rapporteur Member State submitted a draft assessment report to the Commission with a copy to the European Food Safety Authority (hereinafter ‘the Authority’), assessing whether that active substance can be expected to meet the approval criteria provided for in Article 4 of Regulation (EC) No 1107/2009.
Država članica izvjestiteljica dostavila je 27. svibnja 2014. nacrt izvještaja o procjeni Komisiji, pri čemu je primjerak poslala i Europskoj agenciji za sigurnost hrane (dalje u tekstu „Agencija”), u kojem procjenjuje može li se očekivati da ta aktivna tvar ispunjava mjerila za odobravanje iz članka 4. Uredbe (EZ) br. 1107/2009.
The assessment of the additional information by the rapporteur Member State was submitted to the Authority in the format of an updated draft assessment report in February 2015.
Procjena dodatnih informacija koju je provela država članica izvjestiteljica dostavljena je Agenciji u obliku ažuriranog nacrta izvještaja o procjeni u veljači 2015.
On 21 April 2015 the Authority communicated to the applicant, the Member States and the Commission its conclusion on whether the active substance Trichoderma atroviride strain SC1 can be expected to meet the approval criteria provided for in Article 4 of Regulation (EC) No 1107/2009 [2].
Agencija je 21. travnja 2015. podnositelju zahtjeva, državama članicama i Komisiji dostavila svoj zaključak o tome može li se za aktivnu tvar Trichoderma atroviride soj SC1 očekivati da ispunjava mjerila za odobravanje iz članka 4. Uredbe (EZ) br. 1107/2009 [2].
On 10 December 2015 the Commission presented to the Standing Committee on Plants, Animals, Food and Feed the review report for Trichoderma atroviride strain SC1 and a draft Regulation providing that Trichoderma atroviride strain SC1 is approved.
Komisija je 10. prosinca 2015. Stalnom odboru za bilje, životinje, hranu i hranu za životinje predstavila izvješće o pregledu za Trichoderma atroviride soj SC1 i nacrt uredbe kojom se predviđa odobrenje Trichoderma atroviride soj SC1.
It has been established with respect to one or more representative uses of at least one plant protection product containing the active substance, and in particular the uses which were examined and detailed in the review report, that the approval criteria provided for in Article 4 of Regulation (EC) No 1107/2009 are satisfied.
U odnosu na jednu ili više reprezentativnih uporaba najmanje jednog sredstva za zaštitu bilja koje sadržava aktivnu tvar, a posebno na uporabe koje su razmotrene i podrobno opisane u izvješću o pregledu, utvrđeno je da su mjerila za odobravanje iz članka 4. Uredbe (EZ) br. 1107/2009 ispunjena.
It is therefore appropriate to approve Trichoderma atroviride strain SC1.
Stoga je primjereno odobriti Trichoderma atroviride soj SC1.
The Commission further considers that Trichoderma atroviride strain SC1 is a low-risk active substance pursuant to Article 22 of Regulation (EC) No 1107/2009.
Komisija nadalje smatra da je Trichoderma atroviride soj SC1 aktivna tvar niskog rizika u skladu s člankom 22. Uredbe (EZ) br. 1107/2009.
Trichoderma atroviride strain SC1 is not a substance of concern and fulfils the conditions set in point 5 of Annex II to Regulation (EC) No 1107/2009.
Trichoderma atroviride soj SC1 nije tvar koja izaziva zabrinutost te ispunjava uvjete utvrđene točkom 5. Priloga II. Uredbi (EZ) br. 1107/2009.
Trichoderma atroviride strain SC1 is a wild-type strain isolated from decaying hazelnut wood in Italy.
Trichoderma atroviride soj SC1 divlji je soj izoliran od drva lješnjaka u raspadu u Italiji.
It is not pathogenic or virulent to humans or animals.
Nije patogen ni virulentan za ljude i životinje.
It is therefore appropriate to approve Trichoderma atroviride strain SC1 as a low-risk substance for a period of 15 years.
Stoga je primjereno odobriti Trichoderma atroviride soj SC1 kao tvar niskog rizika za razdoblje od 15 godina.
In accordance with Article 13(4) of Regulation (EC) No 1107/2009, the Annex to Commission Implementing Regulation (EU) No 540/2011 [3] should be amended accordingly.
U skladu s člankom 13. stavkom 4. Uredbe (EZ) br. 1107/2009 trebalo bi na odgovarajući način izmijeniti prilog Provedbenoj uredbi Komisije (EU) br. 540/2011 [3].
Approval of a low-risk active substance
Odobrenje aktivne tvari niskog rizika
The active substance Trichoderma atroviride strain SC1, as specified in Annex I, is approved subject to the conditions laid down in that Annex.
Aktivna tvar Trichoderma atroviride soj SC1, kako je navedena u Prilogu I., odobrava se u skladu s uvjetima utvrđenima u tom prilogu.
EFSA Journal 2015;13(4):4092.
EFSA Journal 2015.; 13(4):4092.
Trichoderma atroviride strain SC1
Trichoderma atroviride soj SC1
Accession number CBS 122089 in the collection of the Centraalbureau voor Schimmelcultures (CBS) in Utrecht, The Netherland
Referentni broj CBS 122089 u zbirci „Centraalbureau voor Schimmelcultures” (CBS – Središnji ured za kulture plijesni) u Utrechtu, Nizozemska
CIPAC No: 988
CIPAC br.: 988
minimum concentration 1 × 1010 CFU/g
najmanja koncentracija 1 × 1010 CFU/g
6 July 2016
6. srpnja 2016.
6 July 2031
6. srpnja 2031.
For the implementation of the uniform principles as referred to in Article 29(6) of Regulation (EC) No 1107/2009, the conclusions of the review report on Trichoderma atroviride strain SC1, and in particular Appendices I and II thereof, shall be taken into account.
Za provedbu jedinstvenih načela iz članka 29. stavka 6. Uredbe (EZ) br. 1107/2009 uzimaju se u obzir zaključci izvješća o pregledu za Trichoderma atroviride soj SC1, a posebice njegovi dodaci I. i II.
In this overall assessment Member States shall pay particular attention to the protection of operators and workers, taking into account that microorganisms are considered as potential sensitizers.
Pri cjelokupnoj ocjeni države članice moraju obratiti posebnu pozornost na zaštitu korisnika sredstva i radnika, uzimajući u obzir da se smatra da mikroorganizmi mogu uzrokovati preosjetljivost.
In Part D of the Annex to Implementing Regulation (EU) No 540/2011, the following entry is added:
U dijelu D priloga Provedbenoj uredbi (EU) br. 540/2011 dodaje se sljedeći unos:
Commission Implementing Regulation (EU) 2016/952
Provedbena uredba Komisije (EU) 2016/952
approving the low-risk active substance Saccharomyces cerevisiae strain LAS02 in accordance with Regulation (EC) No 1107/2009 of the European Parliament and of the Council concerning the placing of plant protection products on the market, and amending the Annex to Commission Implementing Regulation (EU) No 540/2011
o odobravanju aktivne tvari niskog rizika Saccharomyces cerevisiae soj LAS02 u skladu s Uredbom (EZ) br. 1107/2009 Europskog parlamenta i Vijeća o stavljanju na tržište sredstava za zaštitu bilja i o izmjeni Priloga Provedbenoj uredbi Komisije (EU) br. 540/2011
In accordance with Article 7(1) of Regulation (EC) No 1107/2009, France received on 9 April 2013 an application from Agrolevures et Dérivés for the approval of the active substance Saccharomyces cerevisiae strain LAS02.
U skladu s člankom 7. stavkom 1. Uredbe (EZ) br. 1107/2009 Francuska je 9. travnja 2013. od subjekta Agro-Levures et Dérivés primila zahtjev za odobrenje aktivne tvari Saccharomyces cerevisiae soj LAS02.
In accordance with Article 9(3) of that Regulation, France, as rapporteur Member State, notified the applicant, the other Member States, the Commission and the European Food Safety Authority (hereinafter ‘the Authority’) of the admissibility of the application on 15 October 2013.
U skladu s člankom 9. stavkom 3. te Uredbe Francuska je, kao država članica izvjestiteljica, 15. listopada 2013. obavijestila podnositelja zahtjeva, ostale države članice, Komisiju i Europsku agenciju za sigurnost hrane (dalje u tekstu „Agencija”) o prihvatljivosti zahtjeva.
On 4 December 2014, the rapporteur Member State submitted a draft assessment report to the Commission with a copy to the Authority, assessing whether that active substance can be expected to meet the approval criteria provided for in Article 4 of Regulation (EC) No 1107/2009.
Država članica izvjestiteljica dostavila je 4. prosinca 2014. nacrt izvještaja o procjeni Komisiji, pri čemu je primjerak poslala Agenciji, u kojem procjenjuje može li se očekivati da ta aktivna tvar ispunjuje mjerila za odobravanje iz članka 4. Uredbe (EZ) br. 1107/2009.
The assessment of the additional information by the rapporteur Member State was submitted to the Authority in the format of an updated draft assessment report on 14 September 2015.
Procjena dodatnih informacija koju je sastavila država članica izvjestiteljica dostavljena je Agenciji u obliku ažuriranog nacrta izvještaja o procjeni dana 14. rujna 2015.
On 3 December 2015, the Authority communicated to the applicant, the Member States and the Commission its conclusion on whether the active substance Saccharomyces cerevisiae strain LAS02 can be expected to meet the approval criteria provided for in Article 4 of Regulation (EC) No 1107/2009 [2].
Agencija je 3. prosinca 2015. podnositelju zahtjeva, državama članicama i Komisiji dostavila svoj zaključak o tome može li se očekivati da aktivna tvar Saccharomyces cerevisiae soj LAS02 ispunjuje mjerila za odobravanje iz članka 4. Uredbe (EZ) br. 1107/2009 [2].
On 7 March 2016, the Commission presented to the Standing Committee on Plants, Animals, Food and Feed the review report for Saccharomyces cerevisiae strain LAS02 and a draft Regulation providing that Saccharomyces cerevisiae strain LAS02 is approved as a low-risk active substance.
Komisija je 7. ožujka 2016. Stalnom odboru za bilje, životinje, hranu i hranu za životinje predstavila izvješće o pregledu za Saccharomyces cerevisiae soj LAS02 i nacrt uredbe kojom se predviđa odobrenje Saccharomyces cerevisiae soj LAS02 kao aktivne tvari niskog rizika.
It is therefore appropriate to approve Saccharomyces cerevisiae strain LAS02.
Stoga je primjereno odobriti Saccharomyces cerevisiae soj LAS02.
The Commission further considers that Saccharomyces cerevisiae strain LAS02 is a low-risk active substance pursuant to Article 22 of Regulation (EC) No 1107/2009.
Komisija nadalje smatra da je Saccharomyces cerevisiae soj LAS02 aktivna tvar niskog rizika u skladu s člankom 22. Uredbe (EZ) br. 1107/2009.
Saccharomyces cerevisiae strain LAS02 is not a substance of concern and fulfils the conditions set in point 5 of Annex II to Regulation (EC) No 1107/2009.
Saccharomyces cerevisiae soj LAS02 nije tvar koja izaziva zabrinutost te ispunjuje uvjete utvrđene točkom 5. Priloga II. Uredbi (EZ) br. 1107/2009.
Saccharomyces cerevisiae strain LAS02 is a naturally occurring yeast, which is widely used in food.
Saccharomyces cerevisiae soj LAS02 prirodni je kvasac koji se u velikoj mjeri upotrebljava u hrani.
It is also widely present in the environment.
U velikoj je mjeri prisutan i u okolišu.
It is therefore appropriate to approve Saccharomyces cerevisiae strain LAS02 as a low-risk substance for a period of 15 years.
Stoga je primjereno odobriti Saccharomyces cerevisiae soj LAS02 kao tvar niskog rizika za razdoblje od 15 godina.
The active substance Saccharomyces cerevisiae strain LAS02, as specified in Annex I, is approved subject to the conditions laid down in that Annex.
Aktivna tvar Saccharomyces cerevisiae soj LAS02, kako je navedena u Prilogu I., odobrava se u skladu s uvjetima utvrđenima u tom Prilogu.
EFSA Journal 2015;13(12):4322.
EFSA Journal 2015.; 13(12):4322.
Saccharomyces cerevisae strain LAS02
Saccharomyces cerevisiae soj LAS02
Accession number in the collection of the ‘Collection Nationale de Cultures de Microorganismes’ (CNCM) of the Pasteur Institute: CNCM I-3936
Referentni broj u zbirci ‚Collection Nationale de Cultures de Microorganismes’ (CNCM – Nacionalna zbirka kultura mikroorganizama) Instituta Pasteur: CNCM I-3936
Minimum concentration: 1 × 1013 CFU/kg
Najniža koncentracija: 1 × 1013 CFU/kg
For the implementation of the uniform principles as referred to in Article 29(6) of Regulation (EC) No 1107/2009, the conclusions of the review report on Saccharomyces cerevisiae strain LAS02, and in particular Appendices I and II thereof, shall be taken into account.
Za provedbu jedinstvenih načela iz članka 29. stavka 6. Uredbe (EZ) br. 1107/2009 uzimaju se u obzir zaključci izvješća o pregledu za Saccharomyces cerevisiae soj LAS02, a posebice njegovi dodaci I. i II.
In this overall assessment Member States shall pay particular attention to the protection of operators and workers, taking into account that Saccharomyces cerevisiae strain LAS02 is to be considered as a potential sensitizer.
U ovoj cjelokupnoj procjeni države članice moraju obratiti posebnu pozornost na zaštitu subjekata i djelatnika, uzimajući u obzir da se smatra da Saccharomyces cerevisiae soj LAS02 može uzrokovati preosjetljivost.
Commission Implementing Regulation (EU) 2016/953
Provedbena uredba Komisije (EU) 2016/953
Commission Delegated Regulation (EU) 2016/957
Delegirana uredba Komisije (EU) 2016/957
supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards for the appropriate arrangements, systems and procedures as well as notification templates to be used for preventing, detecting and reporting abusive practices or suspicious orders or transactions
o dopuni Uredbe (EU) br. 596/2014 Europskog parlamenta i Vijeća u pogledu regulatornih tehničkih standarda za odgovarajuće mjere, sustave i postupke te predloške obavijesti koje treba upotrebljavati za sprečavanje, otkrivanje i prijavljivanje praksi zlouporabe ili sumnjivih naloga odnosno transakcija
Having regard to Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation) and repealing Directive 2003/6/EC of the European Parliament and of the Council and Commission Directives 2003/124/EC, 2003/125/EC and 2004/72/EC [1], and in particular the third subparagraph of Article 16(5) thereof,
uzimajući u obzir Uredbu (EU) br. 596/2014 Europskog parlamenta i Vijeća od 16. travnja 2014. o zlouporabi tržišta (Uredba o zlouporabi tržišta) te stavljanju izvan snage Direktive 2003/6/EZ Europskog parlamenta i Vijeća i direktiva Komisije 2003/124/EZ, 2003/125/EZ i 2004/72/EZ [1], a posebno njezin članak 16. stavak 5. treći podstavak,